Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

by Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M.Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus
Published 2021-02-01